http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CZ-395399-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_07b71571160c289fbf5fc680dfea513f |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N37-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-99 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-00 |
| filingDate | 1998-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57063bdac6b1450b118126653dfff4fb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6ebe1bc51e94b5797fc2ed0f678a52c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ae812f6c653eefb2b0a0f8c74df9fc5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4987967779f6142c2616ba0c917d7a73 |
| publicationDate | 2000-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CZ-395399-A3 |
| titleOfInvention | Protease Inhibitors |
| abstract | The compound of formula (I) wherein Y is Ar or NR 1 V 2,nR 1 is R ", R" QO), R "C (S), R" SO 2, R "OC (O), R" R'NC (O)nor R "RTNQS), R 2 is H, C 1-6 alkyl, C 1-6 alkenyl, Ar-C 1-6 alkyln- or Het-C 1-6 alkyl, R 3 is H, C 1-6 alkenyl, C 1-6 alkynyl, Het, Ar, Cn"Alkyl optionally substituted with C 1-6 ', SR', NR '2, N (R') C (O) OR",nCO2R ', CO2NR', CO2NR '2, N (C = NH) NH2, Het or Ar, R4 isnH, C 1-6 alkyl, C 2-6 alkenyl, Ar-C 1-6 alkyl or Her-C 1-6 alkyl, R 5 isn(a), Ar-C 1-6 alkyl or Het-C 1-6 alkyl, adamantanyl-QO) - ornHet-C (O>, R6 is R ", R" C (O), R "C (S), R" SO 2, R "OQO),nR "RNQO), R" R'NQS) or R "OQO) NR'CH (R *) QO), R7nis C 3-6 cycloalkyl-C 1-6 alkyl, Ar-C 1-6 alkyl, Het-C 1-6 alkyl, Ar-C 0-6 alkyl;n6alkoxy, Het-C 1-6 alkoxy or C 1-4 alkyl optionally substitutednOR ', SR', NR 'N (R') C (O) OR ', CO2R', OO2NR 'n2, N (C = NH) NH 2, lit or Ar, R 1 is H, C 1-6 alkyl, C 1-6 alkenyl, CnCycloalkyl-C 1-6 alkyl, Ar-C 1-6 alkyl, Ar-C 1-6 alkyl or Het-Cp.nC 1-6 alkyl, each R 1 independently is H, C 1-6 alkyl, C 1-6 alkenyl, Ar-C 0-6.nC 1-6 alkyl or Het-C 1-6 alkyl, each R "independently is C 1-6 alkyl, Cyn6cycloalkyl-C 1-6 alkyl, Ar-C 1-6 alkyl or Het-c-alkyl, R "is H, CnC 1-6 alkyl, C 1-6 cycloalkyl-C 1-6 alkyl, Ar-C 1-6 alkyl or Het-Cp.nC 1-6 alkyl, Z is C (O) or CH 2 and n is 1, 2 or 3, or anpharmaceutically acceptable salts that inhibit cysteine proteases,nin particular, cathepsin K, and which are useful in the treatment of diseases, are factoreminhibition loss. |
| priorityDate | 1998-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 414.